- Home
- URGN
URGN
UroGen Pharma Ltd.
as 02-21-2025 4:00pm EST
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | RA'ANANA |
| Market Cap: | 465.9M | IPO Year: | 2017 |
| Target Price: | $42.25 | AVG Volume (30 days): | 281.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.78 - $20.70 | Next Earning Date: | 03-13-2025 |
| Revenue: | $89,363,000 | Revenue Growth: | 15.64% |
| Revenue Growth (this year): | 12.17% | Revenue Growth (next year): | 44.23% |
Stock Insider Trading Activity of UroGen Pharma Ltd. (URGN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Smith Jason Drew | URGN | General Counsel | Jan 31 '25 | Sell | $11.14 | 7,379 | $82,202.06 | 26,468 | |
| Schoenberg Mark | URGN | Chief Medical Officer | Jan 31 '25 | Sell | $11.14 | 4,551 | $50,698.14 | 145,666 |
Latest UroGen Pharma Ltd. News
URGN Breaking Stock News: Dive into URGN Ticker-Specific Updates for Smart Investing
Pharmaceutical Technology
a day ago
UroGen acquires IconOVir’s oncolytic virus assets
MT Newswires
2 days ago
UroGen Pharma Acquires Oncolytic Virus From IconOVir Bio
Business Wire
2 days ago
UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations
Business Wire
8 days ago
UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102
Business Wire
10 days ago
Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology
Business Wire
23 days ago
UroGen Pharma to Present at Upcoming Investor Conferences
Business Wire
a month ago
New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)
Business Wire
a month ago
ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025
Compare URGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "URGN UroGen Pharma Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.